Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inner Mongolia Government Accepts Applications For SHI-Inclusion Of Compound Drugs

This article was originally published in PharmAsia News

Executive Summary

The Department of Human Resources and Social Security of Inner Mongolia has started accepting applications from drug companies for their compound drugs, including infusions, to be covered by the region's Social Health Insurance

You may also be interested in...



Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III

The Phase III clinical trial showed a noticeable placebo effect compared with OV101.

Becton Dickinson Expands Pre-Fillable Syringe Capacity, Anticipating Demand Surge

The company will invest $1.2bn over the next four years to expand and upgrade its manufacturing capacity for pre-fillable syringes and advanced drug delivery systems across seven manufacturing facilities.

CMS Cements In Place Permanent Telehealth Reimbursements In Final Physician Pay Rule

Beneficiaries in nursing homes and in rural areas will benefit from a telehealth expansion in the final CMS physician fee schedule rule.

UsernamePublicRestriction

Register

SC143406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel